8-K: iSpecimen Inc. Faces Nasdaq Delisting Threat Over Sub-Minimum Stockholders' Equity

iSpecimen Inc. has received a notice from Nasdaq indicating non-compliance with listing rules due to its stockholders' equity falling below the required $2.5 million minimum, initiating a 45-day period to submit a compliance plan.

Summary

• iSpecimen Inc. received a notice from The Nasdaq Stock Market LLC on June 4, 2025, indicating non-compliance with Nasdaq Listing Rule 5550(b)(1).
• This rule mandates a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market.
• As reported in the company's Quarterly Report on Form 10-Q for the period ended March 31, 2025, iSpecimen's stockholders' equity was $1,668,513, which is below the required threshold.
• The company also does not currently meet alternative continued listing criteria related to market value of listed securities or net income from continuing operations.
• The Nasdaq notification has no immediate effect on the listing or trading of the company's common stock, which continues to trade under the symbol ISPC.
• iSpecimen has 45 calendar days from the date of the notice to submit a plan to regain compliance.
• If Nasdaq accepts the plan, the company may be granted an extension of up to 180 calendar days from the notice date to evidence compliance.
• The company intends to submit a compliance plan within the required timeframe, but there is no assurance that Nasdaq will accept the plan or that compliance will be regained.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's non-compliance with Nasdaq listing rules, indicating financial distress and the significant risk of delisting. While there's a plan to regain compliance, the outcome is uncertain.

Positives

• The Nasdaq notification has no immediate effect on the listing or trading of the Company's common stock.
• The Company has 45 calendar days to submit a plan to regain compliance, providing an opportunity to address the deficiency.
• If the plan is accepted, the Company may be granted an extension of up to 180 calendar days to achieve compliance.
• The Company will have the opportunity to appeal the determination to a Nasdaq Hearings Panel if its plan is not accepted.

Negatives

• iSpecimen Inc. is non-compliant with Nasdaq Listing Rule 5550(b)(1), requiring a minimum of $2.5 million in stockholders' equity.
• The company's stockholders' equity was $1,668,513 as of March 31, 2025, falling significantly short of the required minimum.
• The company also fails to meet alternative continued listing criteria based on market value of listed securities or net income from continuing operations.
• There is no assurance that Nasdaq will accept the company's compliance plan or that the company will ultimately regain compliance within the applicable period.

Risks

• Risk of delisting from The Nasdaq Stock Market LLC if the company fails to regain compliance with listing rules.
• Uncertainty regarding Nasdaq's acceptance of the company's compliance plan.
• Potential inability to meet compliance requirements within the extended 180-day period, even if a plan is accepted.
• Risk of negative investor perception and potential share price decline due to delisting concerns.

Future Outlook

iSpecimen Inc. intends to submit a plan to Nasdaq within 45 calendar days to regain compliance with the listing rules. However, there is no assurance that Nasdaq will accept the plan or that the company will ultimately regain compliance within the applicable 180-day extension period, if granted.

Management Comments

• "The Company intends to submit a compliance plan within the required timeframe."
• "There can be no assurance that Nasdaq will accept the plan or that the Company will ultimately regain compliance within the applicable period."

Industry Context

This announcement highlights the ongoing scrutiny by stock exchanges like Nasdaq to ensure listed companies maintain minimum financial health standards. Companies in the biotechnology and healthcare services sectors, particularly smaller or emerging ones, often face challenges in maintaining consistent profitability and equity levels, making them susceptible to such listing deficiencies.

Comparison to Industry Standards

• Nasdaq Listing Rule 5550(b)(1) requires a minimum of $2.5 million in stockholders' equity, which is a standard threshold for continued listing on the Nasdaq Capital Market.
• iSpecimen Inc.'s reported stockholders' equity of $1,668,513 as of March 31, 2025, falls significantly short of this standard, indicating a weaker financial position compared to companies that comfortably meet such listing requirements.
• The failure to meet alternative criteria (market value of listed securities or net income from continuing operations) further underscores the company's current financial challenges relative to its peers that maintain compliance through these alternative paths.

Stakeholder Impact

• Shareholders: Face significant risk of share price depreciation and potential loss of liquidity if the company is delisted from Nasdaq.
• Investors: May view the company as a higher-risk investment due to financial instability and delisting concerns.

Next Steps

• iSpecimen Inc. must submit a plan to Nasdaq within 45 calendar days (by approximately July 19, 2025) to regain compliance.
• If the plan is accepted, the company may be granted an extension of up to 180 calendar days (by approximately December 1, 2025) to evidence compliance.
• If the plan is not accepted, the company will have the opportunity to appeal the determination to a Nasdaq Hearings Panel.

Key Dates

Recommendation

Keywords

iSpecimen Inc., ISPC, Nasdaq, Delisting, Stockholders' Equity, Listing Rules, Form 8-K, Compliance Plan, Financial Health, Biotech, Healthcare Services